A Phase 1/2 Study of Pembrolizumab plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-cell Lymphomas
Categories (click each to see list of all clinical trials associated with that category): Lymphoma/Chronic lymphocytic leukemia (CLL)
Current Status: Open to accrual
Phase: I/II
Principal Investigator: Lunning, Matthew
Eligibility: https://www.clinicaltrials.gov/ct2/show/NCT03598998?cond=NCT03598998&draw=2&rank=1#eligibility
Summary